Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) – Expressing Cancers

Cue Biopharma, Inc. announced that the US FDA has accepted the Company’s Investigational New Drug application for the evaluation of CUE-102, its second interleukin 2 (IL-2)-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase I trial, which will have a starting dose of 1 mg/kg for the treatment of Wilms’ Tumor 1-positive recurrent/metastatic cancers, with initial focus on gastric, pancreatic, ovarian and colon cancers.